Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens

Autor: C. Siemes, O. S. Smeekes, L. de Wreede, Martine E.D. Chamuleau, Wendy Stevens, Marcel Nijland, C.A. Uyl-de Groot, Jeanette K. Doorduijn, A. M. P. Demandt, Rolf E. Brouwer, Frederick W. Thielen, Philip M. Kluin, L. Hardi, Marie-Jose Kersten, G. W. van Imhoff, Joke W. Baars, D. de Jong, Liesbeth E M Oosten, Hendrik Veelken
Přispěvatelé: Health Technology Assessment (HTA), Hematology, Interne Geneeskunde, MUMC+: MA Hematologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, CCA - Cancer Treatment and quality of life, AGEM - Re-generation and cancer of the digestive system, Pathology, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Stem Cell Aging Leukemia and Lymphoma (SALL), CCA - Cancer Treatment and Quality of Life, Clinical Haematology
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Male
Survival
medicine.medical_treatment
NETHERLANDS
Cost-Benefit Analysis
MULTICENTER
HIV Infections
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Drugtherapy
ALLOGENEIC TRANSPLANTATION
Stage (cooking)
B-cell lymphoma
Melphalan
Etoposide
Hematology
CODOX-M/IVAC
Cytarabine
Burkitt lymphoma
General Medicine
Middle Aged
3. Good health
030220 oncology & carcinogenesis
Toxicity
Rituximab
Original Article
Female
Drug therapy
medicine.drug
Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
PROTOCOLS
Adult
medicine.medical_specialty
Adolescent
Cost nalysis
03 medical and health sciences
Pharmacotherapy
All institutes and research themes of the Radboud University Medical Center
SDG 3 - Good Health and Well-being
Internal medicine
medicine
Cost analysis
Humans
Ifosfamide
Cyclophosphamide
RESPONSE CRITERIA
Aged
Neoplasm Staging
Retrospective Studies
Chemotherapy
business.industry
B-CELL LYMPHOMA
medicine.disease
Carmustine
Survival Analysis
Lymphoma
Methotrexate
business
LEUKEMIA
COSTS
030215 immunology
Zdroj: Annals of Hematology
Oosten, L E M, Chamuleau, M E D, Thielen, F W, de Wreede, L C, Siemes, C, Doorduijn, J K, Smeekes, O S, Kersten, M J, Hardi, L, Baars, J W, Demandt, A M P, Stevens, W B C, Nijland, M, van Imhoff, G W, Brouwer, R, Uyl-de Groot, C A, Kluin, P M, de Jong, D & Veelken, H 2018, ' Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens ', Annals of Hematology, vol. 97, no. 2, pp. 255-266 . https://doi.org/10.1007/s00277-017-3167-7
Annals of Hematology, 97(2), 255-266. Springer-Verlag
Annals of Hematology, 97(2), 255-266
Annals of Hematology, 97, 2, pp. 255-266
Annals of Hematology, 97, 255-266
Annals of Hematology, 97(2), 255-266. Springer
Annals of Hematology, 97(2), 255-266. Springer Verlag
Annals of Hematology, 97(2), 255-266. SPRINGER
Annals of hematology, 97(2), 255-266. Springer Verlag
ISSN: 0939-5555
Popis: Burkitt lymphoma is an aggressive B cell malignancy accounting for 1–2% of all adult lymphomas. Treatment with dose-intensive, multi-agent chemotherapy is effective but associated with considerable toxicity. In this observational study, we compared real-world efficacy, toxicity, and costs of four frequently employed treatment strategies for Burkitt lymphoma: the Lymphome Malins B (LMB), the Berlin-Frankfurt-Münster (BFM), the HOVON, and the CODOX-M/IVAC regimens. We collected data from 147 adult patients treated in eight referral centers. Following central pathology assessment, 105 of these cases were accepted as Burkitt lymphoma, resulting in the following treatment groups: LMB 36 patients, BFM 19 patients, HOVON 29 patients, and CODOX-M/IVAC 21 patients (median age 39 years, range 14–74; mean duration of follow-up 47 months). There was no significant difference between age, sex ratio, disease stage, or percentage HIV-positive patients between the treatment groups. Five-year progression-free survival (69%, p = 0.966) and 5-year overall survival (69%, p = 0.981) were comparable for all treatment groups. Treatment-related toxicity was also comparable with only hepatotoxicity seen more frequently in the CODOX/M-IVAC group (p = 0.004). Costs were determined by the number of rituximab gifts and the number of inpatients days. Overall, CODOX-M/IVAC had the most beneficial profile with regards to costs, treatment duration, and percentage of patients completing planned treatment. We conclude that the four treatment protocols for Burkitt lymphoma yield nearly identical results with regards to efficacy and safety but differ in treatment duration and costs. These differences may help guide future choice of treatment. Electronic supplementary material The online version of this article (10.1007/s00277-017-3167-7) contains supplementary material, which is available to authorized users.
Databáze: OpenAIRE
Externí odkaz: